How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/hereditary-factor-ix-deficiency-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Hereditary factor IX deficiency disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hereditary factor IX deficiency disease (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Hereditary factor IX deficiency disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	First approval
Idelvion	ALBUTREPENONACOG ALFA	CSL Behring GmbH		2016-01-01
Alprolix	EFTRENONACOG ALFA	Swedish Orphan Biovitrum AB		2016-01-01
Eptacog Alfa	EPTACOG ALFA (ACTIVATED)	Novo Nordisk		1996-01-01
Recombinant Coagulation Factor Ix	nonacog alfa	Pfizer Ltd
Alprolix	Alprolix	Swedish Orphan Biovitrum
Nonacog Alfa (Genetical Recombination)	nonacog-alfa-genetical-recombination	Pfizer Inc.	Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

CSL Behring GmbH · 1 drug in Hereditary factor IX deficiency disease
Novo Nordisk · 1 drug in Hereditary factor IX deficiency disease
Pfizer Inc. · 1 drug in Hereditary factor IX deficiency disease
Pfizer Ltd · 1 drug in Hereditary factor IX deficiency disease
Swedish Orphan Biovitrum · 1 drug in Hereditary factor IX deficiency disease
Swedish Orphan Biovitrum AB · 1 drug in Hereditary factor IX deficiency disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Hereditary factor IX deficiency disease:

Cite this brief

Drug Landscape (2026). Hereditary factor IX deficiency disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/hereditary-factor-ix-deficiency-disease. Accessed 2026-06-10.

Hereditary factor IX deficiency disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing